Winston JS - Search Results

1

HER-2/neu evaluation in breast cancer are we there yet?

Winston JS, Ramanaryanan J, Levine E. Winston JS, et al. Am J Clin Pathol. 2004 Jun;121 Suppl:S33-49. doi: 10.1309/9UNL7UXPYO6CPWBQ. Am J Clin Pathol. 2004. PMID: 15298149 Review.

2

HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.

Tan D, Deeb G, Wang J, Slocum HK, Winston J, Wiseman S, Beck A, Sait S, Anderson T, Nwogu C, Ramnath N, Loewen G. Tan D, et al. Diagn Mol Pathol. 2003 Dec;12(4):201-11. doi: 10.1097/00019606-200312000-00004. Diagn Mol Pathol. 2003. PMID: 14639106

3

Variation of the prognostic significance of HER-2 expression in breast cancer according to tumor size.

Swede H, Moysich KB, Winston JS, Hurd TC, Edge SB, Romero-Gutierrez M, Brooks JS, Michalek AM. Swede H, et al. Among authors: winston js. Breast J. 2003 Mar-Apr;9(2):98-105. doi: 10.1046/j.1524-4741.2003.09207.x. Breast J. 2003. PMID: 12603382

4

Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue.

Dillon DC, Easley SE, Asch BB, Cheney RT, Brydon L, Jockers R, Winston JS, Brooks JS, Hurd T, Asch HL. Dillon DC, et al. Among authors: winston js. Am J Clin Pathol. 2002 Sep;118(3):451-8. doi: 10.1309/1T4V-CT1G-UBJP-3EHP. Am J Clin Pathol. 2002. PMID: 12219788

5

Breast cancer risk factors and HER2 over-expression in tumors.

Swede H, Moysich KB, Freudenheim JL, Quirk JT, Muti PC, Hurd TC, Edge SB, Winston JS, Michalek AM. Swede H, et al. Among authors: winston js. Cancer Detect Prev. 2001;25(6):511-9. Cancer Detect Prev. 2001. PMID: 12132871

6

Calcium oxalate is associated with benign breast tissue. Can we avoid biopsy?

Winston JS, Yeh IT, Evers K, Friedman AK. Winston JS, et al. Am J Clin Pathol. 1993 Nov;100(5):488-92. doi: 10.1093/ajcp/100.5.488. Am J Clin Pathol. 1993. PMID: 8249886

7

Downregulation of gelsolin correlates with the progression to breast carcinoma.

Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A, Asch BB. Winston JS, et al. Breast Cancer Res Treat. 2001 Jan;65(1):11-21. doi: 10.1023/a:1006446108411. Breast Cancer Res Treat. 2001. PMID: 11245335

8

Altered expression and localization of PKC eta in human breast tumors.

Masso-Welch PA, Winston JS, Edge S, Darcy KM, Asch H, Vaughan MM, Ip MM. Masso-Welch PA, et al. Among authors: winston js. Breast Cancer Res Treat. 2001 Aug;68(3):211-23. doi: 10.1023/a:1012265703669. Breast Cancer Res Treat. 2001. PMID: 11727958

9

Concordance with breast cancer pathology reporting practice guidelines.

Wilkinson NW, Shahryarinejad A, Winston JS, Watroba N, Edge SB. Wilkinson NW, et al. Among authors: winston js. J Am Coll Surg. 2003 Jan;196(1):38-43. doi: 10.1016/s1072-7515(02)01627-7. J Am Coll Surg. 2003. PMID: 12517547

10

Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo.

Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS, Li F. Ghadersohi A, et al. Among authors: winston js. Breast Cancer Res Treat. 2007 Mar;102(1):19-30. doi: 10.1007/s10549-006-9314-9. Epub 2006 Aug 8. Breast Cancer Res Treat. 2007. PMID: 16897429 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page